Immuno-Oncology (IO) Market report has been prepared by considering several fragments of the present and upcoming market scenario. The market insights gained through this market research analysis report facilitates more clear understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. It consists of most-detailed market segmentation, thorough analysis of major market players, trends in consumer and supply chain dynamics, and insights about new geographical markets. The market insights covered in Asia-Pacific Protein
Data Bridge Market Research analyses that the immuno-oncology (IO) market, which is USD 28.10 billion in 2022, is expected to reach USD 156.05 billion by 2030, at a CAGR of 23.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Download Sample PDF Copy of this Report to understand structure of the complete report (Including Full TOC, Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-immuno-oncology-market
Market Overview:
Immuno-Oncology (I-O) is an advanced area of research that seeks to help the body's immune system fight cancer. Drugs used for cancer treatment enhance or suppress the immune system to support the body's defenses against cancer, infections, and other diseases. To boost the immune system and help the body find and get rid of cancer cells, it uses substances created by the body or in a lab.
Some of the major players operating in the immuno-oncology (IO) market are:
- Bristol Myers Squibb Company (US.)
- Novartis AG (Switzerland)
- F. Hoffmann-LA Roche Ltd. (Switzerland)
- Merck & Co., Inc. (U.S.)
- GSK Plc. (UK.)
- Eli Lilly and Company (US.)
- Fresenius Kabi AG (Germany)
- Pfizer Inc. (US.)
- AbbVie Inc. (US.)
- Genentech Inc. (U.S.)
- Sanofi (France)
- AstraZeneca (UK.)
Global Immuno-Oncology (IO) Market Dynamics
Drivers
The rise in cancer cases will bolster the market growth
The market for immuno-oncology drugs is projected to expand due to the increase in cancer diagnoses worldwide. For instance, the American Cancer Society predicts that there will be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US in January 2022, or about 1,670 fatalities every day. Lung, prostate, bowel, and female breast cancer are the top four cancer types globally, making up 43% of all new cancer cases. Lung, prostate, bowel, and female breast cancer account for 43% of all new instances of cancer, making them the four most prevalent cancers worldwide. Therefore, it is projected that the rise in cancer incidence rates worldwide will increase the demand for immune-oncology medications.
Rising research and development funding will propel the market growth
Research and development funding is heavily invested in the fight against cancer, particularly precision medicine. Based on a person's genetic profile, precision medicine offers them individualized care. Consequently, the future of cancer treatment is likely to involve a combination of immunotherapy and personalized therapy. Better patient outcomes will surely be observed across a wide range of cancer types due to the advances in cancer management backed by the most recent surgical and radiation technology. These are the certain factors that propel the market growth.
Browse Full Report Along with Facts and Figures @ https://www.databridgemarketresearch.com/reports/global-immuno-oncology-market
TABLE OF CONTENTS
Part 01: Executive Summary
Part 02: Scope of the Report
Part 03: Research Methodology
Part 04: Market Landscape
Part 05: Pipeline Analysis
Part 06: Market Sizing
Part 07: Five Forces Analysis
Part 08: Market Segmentation
Part 09: Customer Landscape
Part 10: Regional Landscape
Part 11: Decision Framework
Part 12: Drivers and Challenges
Part 13: Market Trends
Part 14: Vendor Landscape
Part 15: Vendor Analysis
Part 16: Appendix
Check Complete Table of Contents with List of Table and Figures @ https://www.databridgemarketresearch.com/toc/?dbmr=global-immuno-oncology-market
Browse Trending Reports:
https://www.databridgemarketresearch.com/reports/global-high-density-polyethylene-hdpe-resins-market
About Data Bridge Market Research:
An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.
Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.
Contact Us: -
Data Bridge Market Research
US: +1 888 387 2818
United Kingdom: +44 208 089 1725
Hong Kong: +852 8192 7475
